Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 2/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4346440 | 0.90 | MLYCD (0.44) | MLYCDMAPK14HSP90AA1KMT2ACTSA | |
| SCHEMBL4339591 | 0.88 | MAPK14 (0.51) | MLYCDMAPK14HSP90AA1NPC1RAB9A | |
| SCHEMBL4335452 | 0.87 | PSEN1 (0.46) | MLYCDMAPK14HSP90AA1MEN1NPC1 | |
| SCHEMBL4348725 | 0.86 | MAPK14 (0.50) | MLYCDMAPK14HSP90AA1CTSALMNA | |
| SCHEMBL4339564 | 0.82 | MAPK14 (0.56) | MLYCDMAPK14HSP90AA1 | |
| SCHEMBL4346675 | 0.81 | MAPK14 (0.45) | MLYCDMAPK14HSP90AA1CTSAMAPT | |
| SCHEMBL4334629 | 0.81 | MLYCD (0.51) | MLYCDMAPK14HSP90AA1 | |
| SCHEMBL4339273 | 0.80 | MLYCD (0.43) | MLYCDMAPK14HSP90AA1CTSAMAPT | |
| SCHEMBL4340360 | 0.79 | MAPK14 (0.52) | MLYCDMAPK14HSP90AA1MEN1NPC1 | |
| SCHEMBL4335490 | 0.79 | MAPK14 (0.59) | MLYCDMAPK14HSP90AA1CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2036905-B1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MLYCD 4475/4885MAPK14 43/4885HSP90AA1 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.